Crucible Therapeutics announces the appointment of Dr Cliff Holloway as Chief Executive Officer
Crucible Therapeutics, a biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Dr Cliff Holloway as Chief Executive Officer. Dr Holloway will also join the company’s Board of Directors.
Crucible Therapeutics and SITraN secure £2.3 million Innovate UK Biomedical Catalyst award to develop breakthrough siRNA therapies that address underlying causes of ALS
Crucible Therapeutics, a biotechnology company developing novel gene therapies for neurodegenerative diseases, is pleased to announce that it has been awarded a substantial £2.3M grant from Innovate UK’s Biomedical Catalyst program …
University of Sheffield spinout company Crucible Therapeutics raises £5 million to advance pioneering treatments for neurological diseases
University of Sheffield spinout company, Crucible Therapeutics, a biotechnology company developing novel therapies to treat amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), has secured £5 million financing from Northern Gritstone and Argobio Studio.
